Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
13 hedge funds and large institutions have $6.12M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.
28% less funds holding
Funds holding: 18 → 13 (-5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
73% less capital invested
Capital invested by funds: $22.5M → $6.12M (-$16.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$154K |
| 2 |
Jane Street
New York
|
+$119K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hartree Partners
New York
|
-$12.6M |
| 2 |
Calamos Advisors
Naperville,
Illinois
|
-$2.47M |
| 3 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
-$643K |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$524K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$220K |
IBER.U Hedge Fund Activity: Q3 2022 in Review
13 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q3 2022, worth a combined $6.12M — down 73% from $22.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IBER.U and 0 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Clear Street, adding an estimated $154K. The largest seller was Hartree Partners, exiting entirely with an estimated $12.6M sold.
- 13 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q3 2022, down from 18 in Q2 2022.
- Funds reported $6.12M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q3 2022, down 73% quarter-over-quarter.
- 0 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q3 2022 and 5 closed out, a net change of -5 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q3 2022 was Clear Street, an estimated $154K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q3 2022 was Hartree Partners, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2022.